События 2024 года, которые могут в будущем изменить подходы к терапии агрессивных В-клеточных лимфом

Мангасарова Я.К., Звонков Е.Е. События 2024 года, которые могут в будущем изменить подходы к терапии агрессивных В-клеточных лимфом. Современная Онкология. 2025;27(1):4–7. DOI: 10.26442/18151434.2025.1.203183

© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.

________________________________________________

Mangasarova YaK, Zvonkov EE. 2024 events that may change the clinical practice for aggressive B-cell lymphomas in the future. Journal of Modern Oncology. 2025;27(1):4–7. DOI: 10.26442/18151434.2025.1.203183

Читать PDF

Аннотация

Проведен анализ материала, представленного на международных конференциях по диагностике и лечению агрессивных В-клеточных лимфом в 2024 г.: выделено 13 наиболее ярких и важных событий, которые в будущем могут изменить клиническую практику. Представленные исследования оценивали эффективность новых терапевтических опций диффузной В-крупноклеточной лимфомы как в 1-й линии, так и при рецидиве заболевания. Безусловные фавориты – биспецифические антитела, эффективность и безопасность которых оценивают с различными комбинаторными партнерами с целью формирования оптимальной стратегии использования их на разных этапах терапии. Также выделено 2 наиболее ярких исследования, посвященных CAR T-клеточной терапии.

Ключевые слова: диффузная В-клеточная крупноклеточная лимфома, таргетная терапия, биспецифические антитела, глофитамаб, полатузумаб ведотин, эпкоритамаб, голкадомид, венетоклакс, туцидиностат, СAR T-клеточная терапия, рапкабтаген аутолейцел

________________________________________________

The data presented at the 2024 international conferences on the diagnosis and treatment of aggressive B-cell lymphomas were reviewed; 13 striking and important events that could change clinical practice in the future were identified. The presented studies evaluated the efficacy of new therapies for diffuse large B-cell lymphoma in both first-line therapy and relapse settings. The absolute top pick is bispecific antibodies; their efficacy and safety are evaluated in various combinations to develop an optimal strategy for their use at different stages of therapy. There are also two most striking studies on CAR T-cell therapy.

Keywords: diffuse B-cell large cell lymphoma, targeted therapy, bispecific antibodies, glofitamab, polatuzumab vedotin, epcoritamab, golcadomide, venetoclax, tucidinostat, CAR T-cell therapy, rapcabtagene autoleucel

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11. DOI:10.1038/35000501
2. Руководство NCCN. Режим доступа: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Ссылка активна на 10.02.2025 [Rukovodstvo NCCN. Availble at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Assessed: 10.02.2025 (in Russian)].
3. Amzallag A, Basavanhally T, Westin J, et al. Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL). Blood. 2024;144(Suppl. 1):579. DOI:10.1182/blood-2024-203135
4. First data from subcutaneous epcoritamab+polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) for first-line diffuse large B-cell lymphoma (DLBCL): Epcope NHL-5). Abstract: S239 EHA 2024.
5. Adrian M, Verner E, Giri P, et al. A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics. Blood. 2024;144 (Suppl. 1):582. DOI:10.1182/blood-2024-204930
6. Abramson J, Geyer S, Pederson L, et al. Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701. J Clin Oncol. 2024;42(Suppl. 16). DOI:10.1200/JCO.2024.42.16_suppl.70
7. Zhao W, Zhu J, Song Y, et al. Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study. J Clin Oncol. 2024;42(Suppl. 17):LBA7003. DOI:10.1200/JCO.2024.42.17_suppl.LBA7003
8. Abramson J, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404(10466):1940-54. DOI:10.1016/S0140-6736(24)01774-4
9. Diefenbach C, Caimi PF, Saba NS, et al. Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study. Blood. 2024;144 (Suppl. 1):987. DOI:10.1182/blood-2024-198452
10. Hutchings M, Balari A, Bosch F, et al. Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study. Blood. 2024;144(Suppl. 1):988. DOI:10.1182/blood-2024-194328
11. Zhang M, Tian S, Fu D, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial. Cancer Cell. 2023;41(10):1705-16.e5.
12. Liang J, Shen H, Yin H, et al. Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: a Phase 2 Multicenter Study. ASH Abst.1725
13. Riedell A, Kwon M, Flinn I, et al. Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update. ASH, Abs 67
14. Shah N, Maziarz R, Jacobson C, et al. Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells – Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ASH24 Abs 68

________________________________________________

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11. DOI:10.1038/35000501
2. Rukovodstvo NCCN. Availble at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Assessed: 10.02.2025 (in Russian).
3. Amzallag A, Basavanhally T, Westin J, et al. Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL). Blood. 2024;144(Suppl. 1):579. DOI:10.1182/blood-2024-203135
4. First data from subcutaneous epcoritamab+polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) for first-line diffuse large B-cell lymphoma (DLBCL): Epcope NHL-5). Abstract: S239 EHA 2024.
5. Adrian M, Verner E, Giri P, et al. A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics. Blood. 2024;144 (Suppl. 1):582. DOI:10.1182/blood-2024-204930
6. Abramson J, Geyer S, Pederson L, et al. Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701. J Clin Oncol. 2024;42(Suppl. 16). DOI:10.1200/JCO.2024.42.16_suppl.70
7. Zhao W, Zhu J, Song Y, et al. Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study. J Clin Oncol. 2024;42(Suppl. 17):LBA7003. DOI:10.1200/JCO.2024.42.17_suppl.LBA7003
8. Abramson J, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404(10466):1940-54. DOI:10.1016/S0140-6736(24)01774-4
9. Diefenbach C, Caimi PF, Saba NS, et al. Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study. Blood. 2024;144 (Suppl. 1):987. DOI:10.1182/blood-2024-198452
10. Hutchings M, Balari A, Bosch F, et al. Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study. Blood. 2024;144(Suppl. 1):988. DOI:10.1182/blood-2024-194328
11. Zhang M, Tian S, Fu D, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial. Cancer Cell. 2023;41(10):1705-16.e5.
12. Liang J, Shen H, Yin H, et al. Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: a Phase 2 Multicenter Study. ASH Abst.1725
13. Riedell A, Kwon M, Flinn I, et al. Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update. ASH, Abs 67
14. Shah N, Maziarz R, Jacobson C, et al. Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells – Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ASH24 Abs 68

Авторы

Я.К. Мангасарова*, Е.Е. Звонков

ФГБУ «Научный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия
*v.k.jana@mail.ru

________________________________________________

Yana K. Mangasarova*, Eugene E. Zvonkov

National Medical Research Center for Hematology, Moscow, Russia
*v.k.jana@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.